Results of a multi-institutional phase 1b clinical trial show women with metastatic HER2+ breast cancer respond well to the combina-tion of trastuzumab emtansine and neratinib.
Dr. Shah’s team is preparing data for publication showing that cardiac doses at Cleveland Clinic are lower than the national standard by more than 50 percent.
Dr. Shah’s team is refining the use of intensity-modulated radiation therapy to deliver partial breast irradiation.
The STRIVE study will measure cfNAs and other genomic material in the context of breast imaging to investigate whether a blood test can enhance detection of early breast cancers
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
This complex microsurgery technique may provide relief to patients with lymphedema.
Traditionally, sentinel node biopsies rely on visible, non-fluorescent dyes. With SmartGoggles, surgeons can see both fluorescent and visible light, allowing for a more accurate determination of the depth of the nodes.
As the new a co-chair of the survivorship committee of SWOG, a National Cancer Institute-supported network of cancer researchers, Dr. Moore will prioritize needs identified by cancer survivors.
The Breast Center is conducting a prospective study to evaluate the effectiveness of combination Exparel/Marcaine given as a field block to reduce postoperative pain in mastectomy patients and decrease the need for narcotic use.
A new study the Department of Cellular and Molecular Medicine identifies a never-before described survival pathway in cancer stem cells (CSCs) that may serve as a potential target for new triple-negative breast cancer (TNBC) treatment therapies.
Fear of breast cancer recurrence is common, unrelated to true risk and does not diminish over time. Irrational fear is debilitating in up to half of patients. Providers can help defuse irrational fear by asking several simple questions.